Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

IIR 16-145 – HSR Study

IIR 16-145
Testing a Novel Strategy to Improve Implementation of Medication-Assisted Treatment for Veterans with Opioid Use Disorders in Low Performing Facilities
Hildi J. Hagedorn, PhD
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, MN
Funding Period: July 2017 - June 2021
Currently, the United States is in the midst of an opioid use disorder (OUD) epidemic with the rates of emergency room visits and overdoses related to prescription opioids skyrocketing and the rates of heroin use increasing rapidly. OUD is associated with increased morbidity and mortality, increased HIV and HCV infection rates, and increased criminal behavior. Opioid agonist therapy (OAT) has been shown to be effective in treating OUD and decreasing these negative consequences. While the efficacy of OAT has been established, the predominant problem is that of implementation: too few providers offer or provide OAT to patients with OUD due to patient, provider or system impediments. While the VHA has made great strides in implementation of OAT over the past decade, national treatment rates remain low (30% of those Veterans eligible to receive OAT do) and several facilities continue to have very low prescribing rates.

The objective of this study is to increase the percentage of Veterans with OUD initiating and sustaining OAT in long-term treatment (a minimum of 3 months) in facilities where the current percent of Veterans receiving medication for OUD is low (<15%). This project will not focus on establishing new methadone opioid treatment centers, but rather focus on using intensive external facilitation to increase access to buprenorphine and (in cases where buprenorphine is contraindicated or not acceptable to the patient) naltrexone prescribing. This objective will be accomplished by: 1) implementing intensive external facilitation at 8 low-performing sites and comparing the change in rate of OAT initiation and sustainment to the remaining low performing sites, 2) using formative evaluation methods to refine the intervention for further dissemination, and 3) assessing the cost and budget impact of the intervention.

Eight sites will be selected based on prescribing rates and number of actionable patients (e.g., patients with OUD not currently receiving OAT) to receive the intervention. Remaining low-performing sites will continue to receive implementation as usual (e.g., MHS/OMHO and Academic Detailing interventions).
Administrative data will be used to monitor the proportion of Veterans with OUD initiating and sustaining OAT at all low-performing sites. The intervention will include a site-specific developmental evaluation, a kick-off site visit and 12 months of ongoing facilitation. The developmental evaluation will consist of qualitative interviews with patients, substance use disorders clinic staff, and primary care and general mental health leadership to assess site level barriers. The site visit will include: 1) a review of site-specific barriers and potential
implementation strategies; 2) instruction on using already available dashboards to track prescribing rates and identify actionable patients; and 3) education on OAT, including required education to obtain waivers for buprenorphine prescribing. On-going facilitation will consist of monthly conference calls with individual site teams and expert clinical consultation available via video conferencing. The primary outcomes will be the proportion of Veterans with a diagnosis of OUD initiating and sustaining OAT. Because implementation of OAT
is a current focus of MHS/OMHO and the Academic Detailing Program, the percentage of Veterans with OUD initiating and sustaining OAT is expected to increase at all sites but the increase in the intervention sites is predicted to be significantly greater. Final qualitative interviews and a cost assessment will inform quantitative results.

Barriers identified at the first two sites include: 1) inadequate number of waivered prescribers, 2) lack of staff time to complete waiver training, 3) concern that primary care cannot provide adequate follow-up, 4) primary care providers' belief that OUD should be handled by mental health specialty care providers, and 5) rural location of clinics effects the ability to retain trained staff.

If the aims of this project are achieved, VA will realize a substantial increase in access to gold-standard, evidence-based, life-saving treatment for OUD in facilities where this treatment is currently available to only a very small minority of patients who would benefit. Given the high prevalence and devastating consequences of OUD among Veterans, improving access to gold-standard treatment has the potential to improve health of Veterans and thereby, realize savings in health care costs by decreasing costly emergency room visits and
emergency hospitalizations associated with overdose and other complications of OUD. Increasing access to effective treatment also has the potential to reduce transmission of costly and life-threatening infectious diseases including HIV and HCV. The project will also provide important information regarding the intensity and cost of external facilitation required to promote adoption of OAT by low-performing facilities thus providing a roadmap to best implement access to OAT at the additional low-performing sites. This information may also assist with designing and resourcing implementation strategies for sites that struggle to adopt other evidence based clinical practices. The project has already identified barriers to implementation of OAT and identified strategies to assist sites in overcoming those barriers.

External Links for this Project

NIH Reporter

Grant Number: I01HX002156-01A1

Dimensions for VA

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

Learn more about Dimensions for VA.

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
    Search Dimensions for this project


Journal Articles

  1. Hagedorn HJ, Gustavson AM, Ackland PE, Bangerter A, Bounthavong M, Clothier B, Harris AHS, Kenny ME, Noorbaloochi S, Salameh HA, Gordon AJ. Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities. Journal of general internal medicine. 2022 Nov 1; 37(14):3594-3602. [view]
  2. Hagedorn H, Kenny M, Gordon AJ, Ackland PE, Noorbaloochi S, Yu W, Harris AHS. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Addiction science & clinical practice. 2018 Dec 13; 13(1):25. [view]
  3. Gordon AJ, Kenny M, Dungan M, Gustavson AM, Kelley AT, Jones AL, Hawkins E, Frank JW, Danner A, Liberto J, Hagedorn H. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings. The American journal on addictions. 2022 Mar 1; 31(2):152-158. [view]
  4. Miller WA, Gordon AJ, Clothier BA, Ackland PE, Bounthavong M, Garcia C, Kenny ME, Noorbaloochi S, Hagedorn HJ. Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study. Implementation research and practice. 2023 Sep 14; 4:26334895231199463. [view]
  5. Garcia CC, Bounthavong M, Gordon AJ, Gustavson AM, Kenny ME, Miller W, Esmaeili A, Ackland PE, Clothier BA, Bangerter A, Noorbaloochi S, Harris AHS, Hagedorn HJ. Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorder. Implementation science communications. 2023 Aug 10; 4(1):91. [view]
  6. Gustavson AM, Wisdom JP, Kenny ME, Salameh HA, Ackland PE, Clothier B, Noorbaloochi S, Gordon AJ, Hagedorn HJ. Early impacts of a multi-faceted implementation strategy to increase use of medication treatments for opioid use disorder in the Veterans Health Administration. Implementation science communications. 2021 Feb 15; 2(1):20. [view]
  7. Gustavson AM, Kenny ME, Wisdom JP, Salameh HA, Ackland PE, Gordon AJ, Hagedorn HJ. Fluctuations in barriers to medication treatment for opioid use disorder prescribing over the course of a one-year external facilitation intervention. Addiction science & clinical practice. 2021 Aug 6; 16(1):51. [view]
  8. Gustavson AM, Hagedorn HJ, Jesser LE, Kenny ME, Clothier BA, Bounthavong M, Ackland PE, Gordon AJ, Harris AHS. Healthcare quality measures in implementation research: advantages, risks and lessons learned. Health research policy and systems. 2022 Dec 7; 20(1):131. [view]
  9. Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerdá M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BD. Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study. Addiction (Abingdon, England). 2016 Nov 1; 111(11):2021-2031. [view]
  10. Ackland PE, Kenny ME, Clothier BA, Salameh HA, Boening N, Gordon AJ, Noorbaloochi S, Gustavson AM, Miller W, Hagedorn HJ. What Contributes to Sustainability? Examining Access to Medications for Opioid Use Disorder in Low-Adopting VHA Facilities. Journal of general internal medicine. 2023 Sep 1; 38(12):2647-2654. [view]

DRA: Substance Use Disorders
DRE: Treatment - Implementation, TRL - Applied/Translational
Keywords: Addictive Disorders, Best Practices, Substance Use and Abuse
MeSH Terms: none

Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.